Avascular Necrosis Market Size & Share, by End user (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Type; Treatment; Diagnosis - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Growth Drivers

• Research funding and clinical trials: The avascular necrosis market is stimulated by research funding and clinical trials as they allow for the investigation of new therapeutic strategies and deepen our understanding of the disease's pathophysiology. Consequently, both the public and private sectors are investing heavily. Such efforts include regenerative medicine approaches and advanced surgical techniques. For instance, in September 2023, CIRM invested USD 44 million to enhance research and manufacturing in regenerative medicine in California. In addition, Novoglia, Inc. received a USD 1.4 million award for the development of a cell therapy for ALSP.
  
  It not only works to improve the results for the patients but also encourages collaboration between researchers, clinicians, and pharmaceutical companies in accelerating the identification of suitable treatments. For instance, in November 2024, Exeter research aims to revolutionize hip surgery with robotic assistance. The HIPSTER study is focused on improving the experience of people undergoing total hip replacement surgery to treat severe arthritis. Successful trials will eventually gain further funding and propel avascular necrosis market expansion through the translation of research findings into clinically applicable solutions to manage AVN.
• Emergence of regenerative medicines: The catalyst growth driver for the avascular necrosis market is the effects of multiple therapeutic agents as they ensure overall efficacy in the treatment of cancer. The incorporation of avascular necrosis with chemotherapy or targeted therapies allows clinicians to achieve a better patient outcome, which also encompasses higher response rates and extended survival. For instance, in March 2024, by creating a 3D model of the lesion developed at Yale, healthcare professionals can target avascular necrosis with minimally invasive techniques to protect the integrity and strength of the bone.
  
  New approaches such as stem cell therapy, PRP injections, and tissue engineering are being found to be very promising in helping the healing process and regeneration of vascular supply to the affected regions. For instance, in July 2024, PacBio entered an agreement with Novogene to further move forward in the field of genomics together with applications impacting tissue engineering-related fields such as rare diseases and oncology. These approaches eliminate the shortcomings of traditional treatment modalities and open up the scope for better outcomes and reduced long-term disability.

 Challenges

• Comorbidity issues: The biggest challenge to the avascular necrosis market is comorbidity issues because a patient will mostly have concurrent multiple health conditions which complicate both diagnosis, treatment, and total management. Some common comorbidities, including diabetes, cardiovascular diseases, and obesity, accelerate the progression of AVN and prevent therapeutic interventions from being maximally effective. Patients with such conditions pose a need for more comprehensive, multidisciplinary care that burdens healthcare resources and complicates decision-making. This also complicates the management of AVN which targets each cause of the AVN plus its comorbidity.
• High treatment costs: One of the major challenges facing the avascular necrosis market is the high cost associated with its treatment, for both the patient and healthcare systems, as managing this condition can be quite pricey. Advanced treatments usually involve surgical intervention, in the form of joint replacement and new regenerative therapies, which are costly and often not covered by medical insurance in many places. Thus, these economic and high treatment costs reduce the accessibility of treatment for many patients, especially the deprived classes or underdeveloped countries with minimal medical care. Such expenses in care management and rehabilitation increase the cost of the disorder in terms of finance to the sufferers.